News

Bruker Announces New Results in Deep, Unbiased Plasma Proteomics, PaSER 1.1 Software and New Cross-linking Consumables at US HUPO 2021

- *Roman Fischer of Oxford University demonstrates high-throughput 4D-Proteomics™ on non-depleted, untreated plasma identifying >350 protein groups with short 10-20 minute methods, enabling high throughput, robust biomarker discovery*

- *OmicEra Diagnostics reports running 720 undepleted serum samples from 31 COVID-19 patients over just 12 days on a single timsTOF Pro system at a rate of 60 samples/day, with 502 proteins quantified and 116 proteins with significant changes in expression levels*

- *TIMS/PASEF® processing of plasma samples with the Seer Proteograph™ Product Suite yields unprecedented depth, speed, and scalability, with the identification of >1,700 protein groups*

- *PaSER software version 1.1 released, including performance enhancements and visualization of Mobility-Offset Mass-Aligned (MOMA) analysis in 4D-Proteomics*

- *Enrichable PhoX cross-linker and three cleavable cross-linkers launched, analysis of timsTOF cross-linking data to be supported in MaxQuant and XlinkX for structural proteomics and protein-protein interaction (PPI) research*

BILLERICA, Massachusetts – March 8th, 2021 – At the virtual 17th US HUPO Conference ([US HUPO 2021](#)), [Bruker Corporation](#) (Nasdaq: BRKR) today announces progress with several collaborations in deep, unbiased plasma proteomics, leveraging the speed, sensitivity and dynamic range of 4D-Proteomics™ on timsTOF Pro systems.

New results from a key collaborator, Professor Kirk Hansen of the University of Colorado Anschutz Medical Center, will be presented at Bruker's virtual seminar at US HUPO on Tuesday, March 9th at 2:00 p.m. EST. Registration for the US HUPO Conference is required to attend the event live. Dr. Hansen will present studies of the plasma proteomes of patients infected with COVID-19, as well as a large-cohort comparison of plasma proteome changes in trauma patients.

Dr. Hansen's research reveals protein dynamics in acute injury and disease states with tens of thousands of measurements per sample. Running larger clinical cohorts is illuminating molecular relationships and mechanistic understanding that has the potential to go well beyond current diagnostics.

Professor Hansen commented: "We have only recently re-entered the plasma proteomics space, primarily because of the speed, sensitivity and throughput of the timsTOF Pro. Coupled with the Evosep One, this system is providing the reliability and throughput that we could not achieve just a few years ago."

In early 2021, Bruker announced a breakthrough paper by the Mann-group that demonstrates unbiased, quantitative true single-cell proteomics to address important questions in single-cell biology and pathobiology (www.biorxiv.org/content/10.1101/2020.12.22.423933v1). Bruker intends to launch a high-end, dedicated single-cell *timsTOF* system in early 2022 for unbiased, quantitative single-cell proteomics.

Bruker recently announced a new *Nature Communications* publication by the Mann & Theis groups on the benefits of large-scale peptide Collisional Cross Section (CCS) measurements and machine learning for 4D-Proteomics (doi.org/10.1038/s41467-021-21352-8). Harnessing deep learning, CCS values can now be predicted for any peptide from any organism, forming a basis for advanced 4D-Proteomics workflows that make full use of the additional peptide CCS 4th dimension.


Fig 1: Large-scale peptide CCS measurement with TIMS and PASEF. www.nature.com/articles/s41467-021-21352-

A. PaSER 1.1 Real-Time Proteomics Search

Bruker releases its **PaSER** software v.1.1, which Dr. Chris Adams, Director of Proteomics Business Development at Bruker Daltonics, will present during the US HUPO seminar on March 9th. PaSER is GPU-based and enables proteomics database search in real time, building on Bruker's acquisition of *IP2* software. 'PaSER' stands for **Pa**rallel **S**earch **E**ngine in **R**eal-time, with parallelized, multi-threaded searches on GPUs to obtain results typically faster than the data acquisition. This allows 'run & done' high-throughput 4D-Proteomics with identified peptides and protein groups available as soon as the experiment is complete.

In addition to performance enhancements, PaSER 1.1 includes visualization of 4D data, including MOMA features and search results. A powerful feature of 4D-Proteomics is Mobility-Offset Mass-Aligned (MOMA) analysis, where co-eluting isomeric or isobaric ions, which cannot be distinguished in typical 3D proteomics, are resolved by mobility separation with precise Collision Cross Sections (CCS) at scale.

B. Cross-Linking for Structural Proteomics and Protein-Protein Interactions (PPIs)

Bruker announces the release of new consumables and software for chemical cross-linking of proteins (XL-MS) for the study of protein structure and interactions. The PhoX cross-linker, licensed from the University of Utrecht after development by the groups of Albert Heck and Richard Scheltema, will be commercially available from Bruker this spring. PhoX is an enrichable cross-linker with a phosphonate group that allows purification from the complex mixtures resulting from XL-MS reactions, using metal-bead affinity purification. Such enrichment greatly enhances the ability to detect cross-linked peptides, and collaborative work between the groups of Albert Heck, Richard Scheltema and Bruker has shown that cross-link detection can be enhanced by TIMS separation using caps-PASEF (**MCP**, 20 Jul 2020, 19(10):1677-1687). Bruker will also launch 3 cleavable cross-linkers in the spring, which are preferred by some research groups, as cleavage of cross-linkers in MS/MS experiments results in characteristic mass differences that are easily detected.

Chemical crosslinking data is very complex and automated analysis software is required. A new version of the popular *MaxQuant* software from the group of Professor Juergen Cox at the Max Planck Institute in Martinsried, Germany, also supports the analysis of XL-MS data from timsTOF Pro systems. It is in beta-test, expected to be released in April 2021 to take advantage of 4D-Proteomics for XL-MS work.

C. Progress in Deep, Unbiased Plasma Proteomics

Several research groups have recently presented exciting results on plasma proteomics using a variety of methods.

In February 2021, Professor Roman Fischer of the Target Discovery Institute in the Nuffield Department of Medicine at Oxford University presented "High-Throughput Proteomics During a Pandemic" at Genetic Engineering & Biotech News (genengnews.com). Dr. Fischer discusses high-throughput 4D-Proteomics of several hundred undepleted plasma samples from COVID-19 patients with different disease severity, healthy controls and patients suffering from other pathologies, like sepsis.

Also in February 2021, researchers from OmicEra Diagnostics GmbH in Planegg, Germany, posted a manuscript on MedRxiv "High-resolution longitudinal serum proteome trajectories in COVID-19 reveal patients-specific seroconversion", in which 31 patients were followed longitudinally for an average of 31 days, using high-throughput 4D-Proteomics. This study employed OmicEra´s automated proteomics pipeline coupled with the Evosep One chromatography system running 21 minute gradients to achieve throughput of 60 samples per day.

Using this methodology, 720 undepleted serum samples were run by OmicEra over 12 days on a single timsTOF Pro, with a total of 502 proteins quantified. Some 116 proteins had quantitative changes in expression levels. At US HUPO, Bruker releases an application note on serum proteomics on our collaborative work with OmicEra.

At US HUPO 2021, Seer (www.seer.bio) will present a collaborative poster with Bruker, showing the unique capabilities of Seer's engineered nanoparticles in combination with the TIMS/PASEF® methods. Together, this strategy achieved unbiased, deep and rapid plasma proteome analysis with >1,700 protein groups identified with 90-minute DDA nanoLC-TIMS-MS/MS methods. The combination of Seer's Proteograph Product Suite with the TIMS/PASEF method provides a scalable solution for unbiased and deep proteomics, accessible to nearly any lab, for the first time.

Dr. Chris Adams, Director of Proteomics Business Development at Bruker Daltonics, stated: "It has been rewarding to see the recent rapid advances in the field of plasma proteomics, an area we expect to grow rapidly in liquid biopsy multiomics translational research and biomarker validation. These advances in deep, unbiased plasma proteomics are enabled by the throughput, robustness and unique 4D-Proteomics selectivity and sensitivity advantages of TIMS/PASEF methods."

Links to Bruker events at the virtual US HUPO conference 2021 can be found here:

https://www.bruker.com/en/landingpages/bdal/us-hupo.html.

About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Media Contact:
Petra Scheffer
Bruker Daltonics Marketing Communications

T: +49 (421) 2205-2843
E: petra.scheffer@bruker.com

Investor Contact:
Miroslava Minkova
Director of Investor Relations & Corporate Development
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com